Company: RPTX
Filing Date: 2025-11-14
Form Type: DEFA14A
Source: 0001193125-25-283320
Chunk: 3

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: DEFA14A
Chunk 3
---
 materials to be filed with the SEC in connection with the Transaction. Copies of these documents may be obtained, free of charge, from the SEC or the Company as described in the preceding paragraph.

| Item 9.01 | Financial Statements and Exhibits. |

| Exhibit 
 No.     
 99.1    |     | Description                                                                 
 Press Release dated November 14, 2025                                       |
|:--------|:----|:----------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: November 14, 2025 |     | By: |     | REPARE THERAPEUTICS INC.                                       
 /s/ Steve Forte                                                |
|:------------------------|:----|:----|:----|:---------------------------------------------------------------|
|                         |     |     |     | Steve Forte                                                    
 President, Chief Executive Officer and Chief Financial Officer |

Exhibit 99.1 Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - - Additional portfolio monetization efforts continue - - Company reports 3Q 2025 financial results - - $112.6 million in cash and cash equivalents and marketable securities as of September 30, 2025, as compared to $109.5 million at June 30, 2025 - CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – November 14, 2025 –Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares of Repare (the “Common Shares”). Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash